nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Lisdexamfetamine—Lisinopril—dilated cardiomyopathy	0.32	0.365	CrCrCtD
Dextroamphetamine—Nateglinide—Lisinopril—dilated cardiomyopathy	0.285	0.326	CrCrCtD
Dextroamphetamine—Aspartame—Lisinopril—dilated cardiomyopathy	0.271	0.309	CrCrCtD
Dextroamphetamine—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00228	0.0307	CcSEcCtD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00207	0.0467	CbGpPWpGaD
Dextroamphetamine—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00202	0.0271	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00193	0.026	CcSEcCtD
Dextroamphetamine—ADRA1B—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00176	0.0398	CbGpPWpGaD
Dextroamphetamine—Lightheadedness—Furosemide—dilated cardiomyopathy	0.0017	0.0229	CcSEcCtD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00168	0.0379	CbGpPWpGaD
Dextroamphetamine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00166	0.0223	CcSEcCtD
Dextroamphetamine—Accidental injury—Lisinopril—dilated cardiomyopathy	0.00161	0.0217	CcSEcCtD
Dextroamphetamine—Viral infection—Lisinopril—dilated cardiomyopathy	0.00158	0.0212	CcSEcCtD
Dextroamphetamine—ADRA1A—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00156	0.0353	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00143	0.0322	CbGpPWpGaD
Dextroamphetamine—Irritability—Furosemide—dilated cardiomyopathy	0.00131	0.0177	CcSEcCtD
Dextroamphetamine—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00127	0.0172	CcSEcCtD
Dextroamphetamine—ADRA1A—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00127	0.0286	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00124	0.0168	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00124	0.0167	CcSEcCtD
Dextroamphetamine—Injury—Lisinopril—dilated cardiomyopathy	0.00112	0.0151	CcSEcCtD
Dextroamphetamine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00111	0.015	CcSEcCtD
Dextroamphetamine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00111	0.0149	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00109	0.0146	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00107	0.0145	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00105	0.0142	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00105	0.0142	CcSEcCtD
Dextroamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00104	0.0235	CbGpPWpGaD
Dextroamphetamine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00103	0.0138	CcSEcCtD
Dextroamphetamine—Sweating—Furosemide—dilated cardiomyopathy	0.00102	0.0137	CcSEcCtD
Dextroamphetamine—Urticaria—Spironolactone—dilated cardiomyopathy	0.000988	0.0133	CcSEcCtD
Dextroamphetamine—Irritability—Lisinopril—dilated cardiomyopathy	0.000986	0.0133	CcSEcCtD
Dextroamphetamine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000984	0.0132	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000931	0.0125	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000917	0.0123	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000901	0.0121	CcSEcCtD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000853	0.0193	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000851	0.0115	CcSEcCtD
Dextroamphetamine—Dizziness—Spironolactone—dilated cardiomyopathy	0.000823	0.0111	CcSEcCtD
Dextroamphetamine—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000823	0.0111	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000815	0.011	CcSEcCtD
Dextroamphetamine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000808	0.0109	CcSEcCtD
Dextroamphetamine—Depression—Lisinopril—dilated cardiomyopathy	0.000794	0.0107	CcSEcCtD
Dextroamphetamine—Vomiting—Spironolactone—dilated cardiomyopathy	0.000791	0.0107	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00079	0.0106	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000785	0.0106	CcSEcCtD
Dextroamphetamine—Rash—Spironolactone—dilated cardiomyopathy	0.000785	0.0106	CcSEcCtD
Dextroamphetamine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000784	0.0106	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000781	0.0105	CcSEcCtD
Dextroamphetamine—Headache—Spironolactone—dilated cardiomyopathy	0.000779	0.0105	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000774	0.0104	CcSEcCtD
Dextroamphetamine—Sweating—Lisinopril—dilated cardiomyopathy	0.000763	0.0103	CcSEcCtD
Dextroamphetamine—Agitation—Furosemide—dilated cardiomyopathy	0.000762	0.0103	CcSEcCtD
Dextroamphetamine—Nausea—Spironolactone—dilated cardiomyopathy	0.000739	0.00995	CcSEcCtD
Dextroamphetamine—Phenylpropanolamine—ADRB1—dilated cardiomyopathy	0.000715	0.142	CrCbGaD
Dextroamphetamine—Amphetamine—SLC22A5—dilated cardiomyopathy	0.000709	0.141	CrCbGaD
Dextroamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.0007	0.0158	CbGpPWpGaD
Dextroamphetamine—TAAR1—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000691	0.0156	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Furosemide—dilated cardiomyopathy	0.000691	0.0093	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000677	0.00912	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000676	0.0091	CcSEcCtD
Dextroamphetamine—Ephedrine—ADRB2—dilated cardiomyopathy	0.00067	0.133	CrCbGaD
Dextroamphetamine—Methamphetamine—SLC22A5—dilated cardiomyopathy	0.000657	0.13	CrCbGaD
Dextroamphetamine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000654	0.00881	CcSEcCtD
Dextroamphetamine—Anorexia—Furosemide—dilated cardiomyopathy	0.000645	0.00869	CcSEcCtD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.000622	0.0141	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00062	0.014	CbGpPWpGaD
Dextroamphetamine—Tension—Lisinopril—dilated cardiomyopathy	0.000611	0.00822	CcSEcCtD
Dextroamphetamine—Nervousness—Lisinopril—dilated cardiomyopathy	0.000604	0.00814	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—ADRB1—dilated cardiomyopathy	0.000604	0.12	CrCbGaD
Dextroamphetamine—Somnolence—Furosemide—dilated cardiomyopathy	0.000602	0.0081	CcSEcCtD
Dextroamphetamine—Phenylpropanolamine—ADRB2—dilated cardiomyopathy	0.000601	0.119	CrCbGaD
Dextroamphetamine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000588	0.00792	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000584	0.00787	CcSEcCtD
Dextroamphetamine—Fatigue—Furosemide—dilated cardiomyopathy	0.000584	0.00786	CcSEcCtD
Dextroamphetamine—Tremor—Lisinopril—dilated cardiomyopathy	0.000583	0.00785	CcSEcCtD
Dextroamphetamine—Constipation—Furosemide—dilated cardiomyopathy	0.000579	0.0078	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—TNF—dilated cardiomyopathy	0.000573	0.114	CrCbGaD
Dextroamphetamine—Angioedema—Lisinopril—dilated cardiomyopathy	0.000569	0.00766	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000554	0.00745	CcSEcCtD
Dextroamphetamine—ADRA1A—Endothelin Pathways—ADRB1—dilated cardiomyopathy	0.000553	0.0125	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.000553	0.0125	CbGpPWpGaD
Dextroamphetamine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00055	0.00741	CcSEcCtD
Dextroamphetamine—Urticaria—Furosemide—dilated cardiomyopathy	0.000538	0.00724	CcSEcCtD
Dextroamphetamine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000535	0.00721	CcSEcCtD
Dextroamphetamine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000535	0.00721	CcSEcCtD
Dextroamphetamine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00053	0.00713	CcSEcCtD
Dextroamphetamine—Anxiety—Lisinopril—dilated cardiomyopathy	0.000528	0.00711	CcSEcCtD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.000523	0.0118	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00052	0.0117	CbGpPWpGaD
Dextroamphetamine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000518	0.00698	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000508	0.00684	CcSEcCtD
Dextroamphetamine—Pseudoephedrine—ADRB2—dilated cardiomyopathy	0.000508	0.101	CrCbGaD
Dextroamphetamine—Infection—Lisinopril—dilated cardiomyopathy	0.000505	0.00679	CcSEcCtD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.000504	0.0114	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000499	0.00672	CcSEcCtD
Dextroamphetamine—SLC6A2—Monoamine Transport—AGT—dilated cardiomyopathy	0.000497	0.0112	CbGpPWpGaD
Dextroamphetamine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000496	0.00668	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000491	0.00661	CcSEcCtD
Dextroamphetamine—Asthenia—Furosemide—dilated cardiomyopathy	0.000486	0.00654	CcSEcCtD
Dextroamphetamine—Anorexia—Lisinopril—dilated cardiomyopathy	0.000484	0.00652	CcSEcCtD
Dextroamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000473	0.0107	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.000465	0.0105	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000463	0.00624	CcSEcCtD
Dextroamphetamine—Insomnia—Lisinopril—dilated cardiomyopathy	0.000459	0.00619	CcSEcCtD
Dextroamphetamine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000453	0.0061	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000452	0.0102	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000452	0.0102	CbGpPWpGaD
Dextroamphetamine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000452	0.00608	CcSEcCtD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.000448	0.0101	CbGpPWpGaD
Dextroamphetamine—Dizziness—Furosemide—dilated cardiomyopathy	0.000448	0.00603	CcSEcCtD
Dextroamphetamine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000447	0.00602	CcSEcCtD
Dextroamphetamine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000442	0.00595	CcSEcCtD
Dextroamphetamine—SLC6A3—Monoamine Transport—AGT—dilated cardiomyopathy	0.00044	0.00994	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000439	0.0059	CcSEcCtD
Dextroamphetamine—Fatigue—Lisinopril—dilated cardiomyopathy	0.000438	0.0059	CcSEcCtD
Dextroamphetamine—Constipation—Lisinopril—dilated cardiomyopathy	0.000434	0.00585	CcSEcCtD
Dextroamphetamine—Vomiting—Furosemide—dilated cardiomyopathy	0.00043	0.0058	CcSEcCtD
Dextroamphetamine—Rash—Furosemide—dilated cardiomyopathy	0.000427	0.00575	CcSEcCtD
Dextroamphetamine—Dermatitis—Furosemide—dilated cardiomyopathy	0.000426	0.00574	CcSEcCtD
Dextroamphetamine—Headache—Furosemide—dilated cardiomyopathy	0.000424	0.00571	CcSEcCtD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000424	0.00958	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00042	0.00949	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—ABCC9—dilated cardiomyopathy	0.000416	0.00939	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000415	0.00559	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000407	0.00919	CbGpPWpGaD
Dextroamphetamine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000404	0.00543	CcSEcCtD
Dextroamphetamine—Nausea—Furosemide—dilated cardiomyopathy	0.000402	0.00541	CcSEcCtD
Dextroamphetamine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000402	0.00541	CcSEcCtD
Dextroamphetamine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000402	0.00541	CcSEcCtD
Dextroamphetamine—SLC18A2—Neuronal System—ACTN2—dilated cardiomyopathy	0.000398	0.009	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.000394	0.0089	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.000383	0.00866	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000377	0.00851	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000374	0.00504	CcSEcCtD
Dextroamphetamine—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000371	0.00838	CbGpPWpGaD
Dextroamphetamine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000364	0.00491	CcSEcCtD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00035	0.00791	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000348	0.00468	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000347	0.00785	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000344	0.00777	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000344	0.00777	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00034	0.00769	CbGpPWpGaD
Dextroamphetamine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000336	0.00452	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00033	0.00745	CbGpPWpGaD
Dextroamphetamine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000323	0.00435	CcSEcCtD
Dextroamphetamine—Rash—Lisinopril—dilated cardiomyopathy	0.00032	0.00431	CcSEcCtD
Dextroamphetamine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00032	0.00431	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00032	0.00723	CbGpPWpGaD
Dextroamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000318	0.00719	CbGpPWpGaD
Dextroamphetamine—Headache—Lisinopril—dilated cardiomyopathy	0.000318	0.00428	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000318	0.00718	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00031	0.007	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00031	0.007	CbGpPWpGaD
Dextroamphetamine—Nausea—Lisinopril—dilated cardiomyopathy	0.000302	0.00406	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000282	0.00637	CbGpPWpGaD
Dextroamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000282	0.00637	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000265	0.00598	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000251	0.00567	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—ABCC9—dilated cardiomyopathy	0.000248	0.00559	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000247	0.00558	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000244	0.00552	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00024	0.00543	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00024	0.00543	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00024	0.00543	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—ACTN2—dilated cardiomyopathy	0.000237	0.00536	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Endothelin Pathways—RAF1—dilated cardiomyopathy	0.000231	0.00521	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—RAC1—dilated cardiomyopathy	0.00023	0.00521	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Monoamine Transport—TNF—dilated cardiomyopathy	0.000225	0.00509	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000223	0.00505	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.000213	0.00482	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.000203	0.00459	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Monoamine Transport—TNF—dilated cardiomyopathy	0.0002	0.00451	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000194	0.00439	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000194	0.00439	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000186	0.00421	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000186	0.00421	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000181	0.00408	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—RAC1—dilated cardiomyopathy	0.00018	0.00407	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000177	0.00399	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000177	0.00399	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000175	0.00395	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000166	0.00375	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000166	0.00374	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000164	0.00371	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000162	0.00365	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000162	0.00365	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000159	0.00359	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000154	0.00347	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000151	0.00341	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00015	0.0034	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00015	0.00338	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000147	0.00333	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000143	0.00324	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000143	0.00324	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000142	0.0032	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000137	0.00309	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000136	0.00307	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000134	0.00303	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000133	0.00301	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000133	0.00301	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000133	0.003	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000129	0.00291	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000124	0.0028	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00012	0.00271	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000119	0.00268	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000118	0.00268	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000118	0.00267	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.000118	0.00266	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000117	0.00265	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000114	0.00258	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000114	0.00258	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00011	0.00249	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00011	0.00249	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000107	0.00241	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000106	0.0024	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000105	0.00238	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000105	0.00238	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000105	0.00237	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000104	0.00236	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000104	0.00236	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000103	0.00232	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000103	0.00232	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000102	0.00229	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000102	0.00229	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.0001	0.00226	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	9.73e-05	0.0022	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.7e-05	0.00219	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—AGT—dilated cardiomyopathy	9.55e-05	0.00216	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	9.44e-05	0.00213	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.39e-05	0.00212	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—AGT—dilated cardiomyopathy	9.34e-05	0.00211	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	9.14e-05	0.00206	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	9.11e-05	0.00206	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—RAF1—dilated cardiomyopathy	9.06e-05	0.00205	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	8.79e-05	0.00199	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	8.7e-05	0.00197	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	8.7e-05	0.00197	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	8.64e-05	0.00195	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	8.35e-05	0.00189	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	8.34e-05	0.00188	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	8.3e-05	0.00187	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	8.09e-05	0.00183	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.02e-05	0.00181	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	7.84e-05	0.00177	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	7.81e-05	0.00176	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	7.73e-05	0.00175	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	7.73e-05	0.00175	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.61e-05	0.00172	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	7.42e-05	0.00168	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	7.41e-05	0.00167	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	7.19e-05	0.00162	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	7.05e-05	0.00159	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	6.96e-05	0.00157	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	6.69e-05	0.00151	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.63e-05	0.0015	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.54e-05	0.00148	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	6.35e-05	0.00143	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	6.18e-05	0.0014	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	5.95e-05	0.00134	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RAC1—dilated cardiomyopathy	5.91e-05	0.00133	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.8e-05	0.00131	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AGT—dilated cardiomyopathy	5.64e-05	0.00127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	5.64e-05	0.00127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	5.49e-05	0.00124	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	5.4e-05	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	5.15e-05	0.00116	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.92e-05	0.00111	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.92e-05	0.00111	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	4.87e-05	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—AGT—dilated cardiomyopathy	4.71e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.57e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.55e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	4.53e-05	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	4.47e-05	0.00101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	4.47e-05	0.00101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	4.43e-05	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	4.37e-05	0.000987	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	4.37e-05	0.000987	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	4.26e-05	0.000963	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—AGT—dilated cardiomyopathy	4.18e-05	0.000945	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	4.15e-05	0.000938	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	4.06e-05	0.000917	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	4.02e-05	0.000908	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	3.98e-05	0.000898	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	3.97e-05	0.000896	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	3.97e-05	0.000896	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	3.93e-05	0.000889	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RAF1—dilated cardiomyopathy	3.92e-05	0.000885	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	3.86e-05	0.000871	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.78e-05	0.000854	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	3.69e-05	0.000833	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.59e-05	0.000811	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	3.57e-05	0.000807	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	3.53e-05	0.000798	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.43e-05	0.000776	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	3.36e-05	0.000759	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.28e-05	0.000741	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	3.26e-05	0.000736	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	3.19e-05	0.00072	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	3.05e-05	0.000689	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.97e-05	0.000671	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.9e-05	0.000656	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	2.89e-05	0.000654	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.79e-05	0.000629	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.69e-05	0.000607	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.66e-05	0.000601	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	2.64e-05	0.000596	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.64e-05	0.000596	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.64e-05	0.000596	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.53e-05	0.000571	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	2.47e-05	0.000559	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.45e-05	0.000554	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AGT—dilated cardiomyopathy	2.42e-05	0.000546	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.38e-05	0.000537	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	2.36e-05	0.000534	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	2.34e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	2.34e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	2.25e-05	0.000508	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	2.18e-05	0.000492	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AGT—dilated cardiomyopathy	2.15e-05	0.000485	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.11e-05	0.000477	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.03e-05	0.000458	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.92e-05	0.000435	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.8e-05	0.000407	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.71e-05	0.000386	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.68e-05	0.000379	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.65e-05	0.000374	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RAC1—dilated cardiomyopathy	1.49e-05	0.000338	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	1.49e-05	0.000337	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.47e-05	0.000332	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AGT—dilated cardiomyopathy	1.43e-05	0.000323	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RAC1—dilated cardiomyopathy	1.33e-05	0.0003	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AGT—dilated cardiomyopathy	1.27e-05	0.000286	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.15e-05	0.00026	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.05e-05	0.000237	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.02e-05	0.000231	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.02e-05	0.00023	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RAF1—dilated cardiomyopathy	9.91e-06	0.000224	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	9.18e-06	0.000207	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RAF1—dilated cardiomyopathy	8.8e-06	0.000199	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGFR—dilated cardiomyopathy	6.8e-06	0.000153	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGFR—dilated cardiomyopathy	6.04e-06	0.000136	CbGpPWpGaD
